Selective Btk inhibitor, ONO/GS-4059: Preclinical evidence supporting the combination with Idelalisib and obinutuzumab
Gespeichert in:
| Veröffentlicht in: | Annals of oncology 2016-11, Vol.27, p.vii30 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | vii30 |
| container_title | Annals of oncology |
| container_volume | 27 |
| creator | Yoshizawa, Toshio |
| description | |
| doi_str_mv | 10.1093/annonc/mdw476 |
| format | Article |
| fullrecord | <record><control><sourceid>crossref</sourceid><recordid>TN_cdi_crossref_primary_10_1093_annonc_mdw476</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>10_1093_annonc_mdw476</sourcerecordid><originalsourceid>FETCH-LOGICAL-c776-d265ed893ef72b8734d8332b44d4819c7a0204113efbead66e03e7842d777bfe3</originalsourceid><addsrcrecordid>eNot0E9PwjAcxvEeNBHRo_e-ACddW9bVmxJFEiImcF_65zepbi1pO4i8ejF4eg7f5Dl8ELoryUNJJJso74M3k94euKgu0IhIygoxZfwKXaf0RQipJJUjtF9DBya7PeDn_I2d3zrtcoj3ePW-mszXBSdT-Yg_IpjOeWdUh2HvLHgDOA27XYjZ-U-ct4BN6LXzKrvg8cHlLV5Y6FTnktNYeYvDqQ55OA690jfoslVdgtv_HaPN68tm9lYsV_PF7GlZGCGqwtJqCraWDFpBdS0YtzVjVHNueV1KIxShhJflqWtQtqqAMBA1p1YIoVtgY1Scb00MKUVom110vYo_TUmaP6fm7NScndgvJB5hXg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Selective Btk inhibitor, ONO/GS-4059: Preclinical evidence supporting the combination with Idelalisib and obinutuzumab</title><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Yoshizawa, Toshio</creator><creatorcontrib>Yoshizawa, Toshio</creatorcontrib><identifier>ISSN: 0923-7534</identifier><identifier>DOI: 10.1093/annonc/mdw476</identifier><language>eng</language><ispartof>Annals of oncology, 2016-11, Vol.27, p.vii30</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids></links><search><creatorcontrib>Yoshizawa, Toshio</creatorcontrib><title>Selective Btk inhibitor, ONO/GS-4059: Preclinical evidence supporting the combination with Idelalisib and obinutuzumab</title><title>Annals of oncology</title><issn>0923-7534</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><recordid>eNot0E9PwjAcxvEeNBHRo_e-ACddW9bVmxJFEiImcF_65zepbi1pO4i8ejF4eg7f5Dl8ELoryUNJJJso74M3k94euKgu0IhIygoxZfwKXaf0RQipJJUjtF9DBya7PeDn_I2d3zrtcoj3ePW-mszXBSdT-Yg_IpjOeWdUh2HvLHgDOA27XYjZ-U-ct4BN6LXzKrvg8cHlLV5Y6FTnktNYeYvDqQ55OA690jfoslVdgtv_HaPN68tm9lYsV_PF7GlZGCGqwtJqCraWDFpBdS0YtzVjVHNueV1KIxShhJflqWtQtqqAMBA1p1YIoVtgY1Scb00MKUVom110vYo_TUmaP6fm7NScndgvJB5hXg</recordid><startdate>201611</startdate><enddate>201611</enddate><creator>Yoshizawa, Toshio</creator><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>201611</creationdate><title>Selective Btk inhibitor, ONO/GS-4059: Preclinical evidence supporting the combination with Idelalisib and obinutuzumab</title><author>Yoshizawa, Toshio</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c776-d265ed893ef72b8734d8332b44d4819c7a0204113efbead66e03e7842d777bfe3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yoshizawa, Toshio</creatorcontrib><collection>CrossRef</collection><jtitle>Annals of oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yoshizawa, Toshio</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Selective Btk inhibitor, ONO/GS-4059: Preclinical evidence supporting the combination with Idelalisib and obinutuzumab</atitle><jtitle>Annals of oncology</jtitle><date>2016-11</date><risdate>2016</risdate><volume>27</volume><spage>vii30</spage><pages>vii30-</pages><issn>0923-7534</issn><doi>10.1093/annonc/mdw476</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0923-7534 |
| ispartof | Annals of oncology, 2016-11, Vol.27, p.vii30 |
| issn | 0923-7534 |
| language | eng |
| recordid | cdi_crossref_primary_10_1093_annonc_mdw476 |
| source | EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| title | Selective Btk inhibitor, ONO/GS-4059: Preclinical evidence supporting the combination with Idelalisib and obinutuzumab |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T09%3A35%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-crossref&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Selective%20Btk%20inhibitor,%20ONO/GS-4059:%20Preclinical%20evidence%20supporting%20the%20combination%20with%20Idelalisib%20and%20obinutuzumab&rft.jtitle=Annals%20of%20oncology&rft.au=Yoshizawa,%20Toshio&rft.date=2016-11&rft.volume=27&rft.spage=vii30&rft.pages=vii30-&rft.issn=0923-7534&rft_id=info:doi/10.1093/annonc/mdw476&rft_dat=%3Ccrossref%3E10_1093_annonc_mdw476%3C/crossref%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |